The Dutch Pancreas Biobank Within the Parelsnoer Institute

Strijker, Marin; Gerritsen, Arja; Hilst, Jony van; Bijlsma, Maarten F.; Bonsing, Bert A.; Brosens, Lodewijk A.A.; Bruno, Marco J.; Dam, Ronald M. van; Dijk, Frederike; Eijck, Casper H. van; Sarasqueta, Arantza Fariña; Fockens, Paul; Gerhards, Michael F.; Koerkamp, Bas Groot; Harst, Erwin van der; Hingh, Ignace H. J. T. de; Hooft, Jeanin E. van; Huysentruyt, Clément J.R.; Kazemier, Geert; Klaase, Joost M.; Laarhoven, Cornelis J. van; Laarhoven, Hanneke W. van; Liem, Mike S L; Meijer, Vincent E de; Rijssen, L.B. van; Santvoort, Hjalmar C. van; Suker, Mustafa; Verhagen, Judith H E; Verheij, Joanne; Verspaget, Hein W.; Wennink, Roos A.W.; Wilmink, Johanna W.; Molenaar, I.; Boermeester, Marja A.; Busch, Olivier R.; Besselink, Marc G.

doi:10.1097/mpa.0000000000001018

Cited by 9 publications

(3 citation statements)

References 34 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Samples were collected in the period between November 2011 and December 2014. In the PancreasParel cohort, 31 patients who underwent resection because of nonmetastatic PDAC (or chronic pancreatitis) in the period between March 2015 and December 2017 and whose serum sample was collected less than 30 days before resection were included. Only patients with a tumor located in the pancreas and histologically confirmed PDAC were included in the analysis.…”

Section: Methodsmentioning

confidence: 99%

See 1 more Smart Citation

Serum levels of iCAF‐derived osteoglycin predict favorable outcome in pancreatic cancer

Dings

Manoukian

Waasdorp

et al. 2022

Intl Journal of Cancer

Self Cite

View full text Add to dashboard Cite

Pancreatic ductal adenocarcinoma (PDAC) is characterized by abundant stroma, the main cellular constituents of which are cancer-associated fibroblasts (CAFs). Stromatargeting agents have been proposed to improve the poor outcome of current treatments. However, clinical trials using these agents showed disappointing results.Abbreviations: CA19.9, carbohydrate antigen 19-9; CAF, cancer-associated fibroblast; CXCL12, platelet factor 12; ELISA, enzyme-linked immunosorbent assay; FABP4, fatty acid binding protein 4; GEO, Gene Expression Omnibus; hg38, homo sapiens (human) genome assembly GRCh38; HR, hazard ratio; IL6, interleukin-6; KD, knock-down; MEF, mouse embryonic fibroblast; MHC-II, antigen-presenting major histocompatibility complex class II; mm10, Mus musculus (house mouse) genome assembly GRCm38; OGN, human osteoglycin protein (gene; OGN); Ogn, mouse osteoglycin protein (gene; Ogn); PDAC, pancreatic ductal adenocarcinoma; PDGFR, platelet-derived growth factor receptor; PDX, patient-derived xenograft; RT-qPCR, quantitative reverse transcription-PCR.

show abstract

Section: Methodsmentioning

confidence: 99%

“…The study was approved by the Dutch Pancreas Biobank scientific committee. For the PancreasParel, the use of residual material from an earlier issuance for which local approvals were obtained 31 was accepted by the Dutch Pancreatic Cancer Group committee. In all cases, written informed consent was received from all participants.…”

Section: Ethics Statementmentioning

confidence: 99%

Serum levels of iCAF‐derived osteoglycin predict favorable outcome in pancreatic cancer

Dings

Manoukian

Waasdorp

et al. 2022

Intl Journal of Cancer

Self Cite

View full text Add to dashboard Cite

show abstract

“…Early research in T1D was originally based on limited human pancreatic specimens (Foulis and Stewart, 1984;Foulis et al, 1986), experimental mouse models [mainly the non-obese diabetic (NOD) mouse (Anderson and Bluestone, 2005)], or on beta cell lines (Scharfmann et al, 2019). During the last decades, the scientific community realized the importance of systematic organ collection and distribution for research and founded several biobanks, such as the Exeter Archival Diabetes Biobank (EADB) (Foulis et al, 1986), the Dutch Pancreas Biobank (Strijker et al, 2018), and the IMIDIA Biobank (Solimena et al, 2018). The National Institutes of Health established the Human Pancreas Analysis Program (HPAP), which aims to distribute high quality molecular data derived from human pancreata in order to enable scientific discovery (Kaestner et al, 2019).…”

Section: Introductionmentioning

confidence: 99%

Whole-Slide Image Analysis of Human Pancreas Samples to Elucidate the Immunopathogenesis of Type 1 Diabetes Using the QuPath Software

Apaolaza

Πετροπούλου

Rodríguez-Calvo

2021

Front. Mol. Biosci.

View full text Add to dashboard Cite

Type 1 diabetes is a chronic disease of the pancreas characterized by the loss of insulin-producing beta cells. Access to human pancreas samples for research purposes has been historically limited, restricting pathological analyses to animal models. However, intrinsic differences between animals and humans have made clinical translation very challenging. Recently, human pancreas samples have become available through several biobanks worldwide, and this has opened numerous opportunities for scientific discovery. In addition, the use of new imaging technologies has unraveled many mysteries of the human pancreas not merely in the presence of disease, but also in physiological conditions. Nowadays, multiplex immunofluorescence protocols as well as sophisticated image analysis tools can be employed. Here, we described the use of QuPath—an open-source platform for image analysis—for the investigation of human pancreas samples. We demonstrate that QuPath can be adequately used to analyze whole-slide images with the aim of identifying the islets of Langerhans and define their cellular composition as well as other basic morphological characteristics. In addition, we show that QuPath can identify immune cell populations in the exocrine tissue and islets of Langerhans, accurately localizing and quantifying immune infiltrates in the pancreas. Therefore, we present a tool and analysis pipeline that allows for the accurate characterization of the human pancreas, enabling the study of the anatomical and physiological changes underlying pancreatic diseases such as type 1 diabetes. The standardization and implementation of these analysis tools is of critical importance to understand disease pathogenesis, and may be informative for the design of new therapies aimed at preserving beta cell function and halting the inflammation caused by the immune attack.

show abstract

Preoperative serum ADAM12 levels as a stromal marker for overall survival and benefit of adjuvant therapy in patients with resected pancreatic and periampullary cancer

Strijker

Sijde

Suker

et al. 2021

HPB

Self Cite

View full text Add to dashboard Cite

Background: We evaluated the stroma marker A Disintegrin And Metalloprotease 12 (ADAM12) as a preoperative prognostic and treatment-predictive marker for overall survival (OS) in pancreatic ductal adenocarcinoma (PDAC) and periampullary cancers.Methods: Materials were derived from the prospective nationwide Dutch Pancreas Biobank (2015)(2016)(2017). We included patients who underwent resection because of PDAC/periampullary cancer or non-invasive IPMN (control group) and had a preoperative serum sample available. ADAM12 levels were dichotomized using a pre-defined cut-off (316 pg/mL). Univariable and multivariable Cox regression analyses (backward selection) were performed.Results: Median ADAM12 levels were 161 (IQR 79-352) pg/mL in 215 PDAC and periampullary adenocarcinomas. High ADAM12 levels (>316 pg/mL) predicted poor OS in the total group of pancreatic and periampullary adenocarcinomas (P = 0.04), but not after adjustment. In distal cholangiocarcinoma (n = 33), high ADAM12 levels predicted poor OS in univariable analysis (P = 0.02), but not in PDAC (P = 0.63). PDAC patients (n = 135) with high ADAM12 levels benefited from adjuvant treatment (median OS 27 vs 14 months, P = 0.02), whereas those with low levels did not (21 vs 21 months, P = 0.87). Conclusion: High circulating ADAM12 levels, as a proxy for activated stroma, predict survival benefit from adjuvant chemotherapy in PDAC, requiring validation in future studies.

show abstract

The Dutch Pancreas Biobank Within the Parelsnoer Institute

Abstract: Prospective collection of biomaterials and associated clinical data has started in the Dutch Pancreas Biobank. Subsequent translational research will aim to improve treatment decisions based on disease characteristics.

Cited by 9 publications

References 34 publications

Serum levels of iCAF‐derived osteoglycin predict favorable outcome in pancreatic cancer

Serum levels of iCAF‐derived osteoglycin predict favorable outcome in pancreatic cancer

Whole-Slide Image Analysis of Human Pancreas Samples to Elucidate the Immunopathogenesis of Type 1 Diabetes Using the QuPath Software

Preoperative serum ADAM12 levels as a stromal marker for overall survival and benefit of adjuvant therapy in patients with resected pancreatic and periampullary cancer

Contact Info

Product

Resources

About